A nucleic acid photocross-linking technology was used in the development of a direct assay for factor V Leiden, a point mutation in the factor V gene (G1691A) that is the most common inherited risk factor for thrombosis. This cross-linking hybridization assay included two allele-specific capture probes and six signal-generating reporter probes; all were modified with a photoactivated cross-linking compound. By using two different capture probes complementary to a 16-base sequence at the factor V Leiden mutation site, but differing in the nucleotide opposite the mutation site (C vs T), wild-type and factor V Leiden alleles were differentiated in purified DNA specimens. The assay was also successfully applied to genomic DNA in leukocytes isolated from whole blood; the factor V status of 122 patients as determined by this method was in complete concordance with a standard PCR-based assay and clearly discriminated between healthy individuals and factor V Leiden heterozygotes.
Resistance to activated protein C (APC) is the most common cause of inherited thrombophilia recognized to date [1] [2] [3] [4] [5] , and the factor V Leiden mutation, a G-to-A transition at position 1691 of exon 10 in the factor V gene, is responsible for Ͼ90% of individuals with resistance to APC [5] . 3 This mutation results in the substitution of glutamine for arginine at position 506 in the amino acid sequence of the coagulation factor V protein. Arginine 506 resides at one of the cleavage sites for inactivation of the clotting cofactor Va by the natural anticoagulant protein, APC [6] . The glutamine substitution has been shown to decrease the rate of inactivation of Va by APC, causing a shift in the hemostatic balance toward a hypercoagulable state, thus providing a mechanism for the increased risk of thrombosis in these individuals [7] .
There is considerable ethnic variation in the prevalence of factor V Leiden. Although the mutation is rare in Asian and African populations, 3-5% of individuals in the American population are heterozygous for this mutation [8] . If one selects individuals with a history of venous thrombosis, the prevalence increases to ϳ20%; the incidence of this mutation approaches 50% for individuals who also have a family history of venous thrombosis [5] .
Current methods of detection for factor V Leiden are labor intensive, requiring purification of genomic DNA from peripheral blood leukocytes, amplification by PCR of the region of the factor V gene flanking the factor V Leiden mutation site, and analysis of the amplification products by gel electrophoresis coupled with either restriction enzyme digestion or hybridization with allelespecific oligonucleotide probes [9] . In addition, current "home brew" methods are time consuming and expensive, suffer from a lack of standardization, and require a level of expertise and equipment not routinely available outside academic medical centers. Since factor V Leiden is the most common cause of inherited thrombophilia yet identified, a simple test to determine the factor V genotype would be a valuable asset in identifying those individuals predisposed to the condition. In an attempt to simplify and standardize testing for factor V Leiden, we have developed a direct detection assay for the presence of the factor V Leiden point mutation. The assay involves a novel nucleic acid cross-linking technology and requires no prior purification or amplification of the genomic DNA.
Materials and Methods patient samples
group of individuals had a 20% prevalence of factor V Leiden, consistent with reports from other institutions testing similar patient groups [5, 10] . Peripheral blood was collected into EDTA tubes and either assayed the same day or after storage for 3 days at 4°C. Alternatively, leukocytes were isolated from fresh blood and stored at Ϫ70°C for 3 days before testing.
oligonucleotide synthesis
Oligonucleotides complementary to sequences within exon 10 and intron 10 of the factor V gene were synthesized on a PerSeptive Expedite 8909 Synthesizer using Expedite DNA synthesis reagents (PerSeptive Biosystems). Two types of oligomer were synthesized: 1) Allele-specific capture probes complementary to nucleotides 1683-1698 of either the normal factor V gene or the mutant factor V (Leiden) gene. These probes contained a biotin molecule at the 3Ј terminus (BioTEG CPG; Glen Research) and a photoactive coumarin crosslinking agent that was positioned opposite the thymidine residue at position 1697 of the exon 10 sequence (in place of the normal dA residue). To allow incorporation of the cross-linker into the oligonucleotides during automated synthesis, a fully protected phosphoramidite derived from 7-hydroxy coumarin,
2) Cross-linker-modified reporter probes complementary to non-allele-specific regions of exon 10 and intron 10 of the factor V gene. These probes were fluoresceinated at the 5Ј terminus during synthesis (Fluorescein CE Phosphoramidite; Cruachem). Six reporter probes were synthesized; these were complementary to nucleotides 1448 -1468, 1514 -1537, 1558 -1580, and 1699 -1623 of exon 10 and to nucleotides 61-82 and 89 -111 of intron 10.
After synthesis, the probes were cleaved from the solid support and deprotected by incubating the support in concentrated ammonium hydroxide for 30 min at 55°C. The fully deprotected probes were purified via electrophoresis through denaturing polyacrylamide gels, followed by excision of the product bands and elution of the products [11] . The purified oligonucleotides were desalted by Sep-Pak C18 treatment with the procedure recommended by the manufacturer (Waters Corp.).
cross-linking hybridization assay procedure
Sample preparation. Red blood cells were lysed by the sequential addition of one volume of erythrocyte lysis buffer (320 mmol/L saccharose, 5 mmol/L MgCl 2 , 10 mmol/L Tris-HCl pH 7.5, 10 mL/L Triton X-100) and three volumes of water to one volume (0.5-4 mL) of whole blood. After a 10-min incubation on ice, the samples were centrifuged at 1500g. The supernatant was decanted and the leukocyte pellet resuspended in 750 L of 1ϫ sodium saline citrate (SSC) buffer (150 mmol/L NaCl, 15 mmol/L sodium citrate, pH 7.0). The cell suspension was transferred to a 2-mL microcentrifuge tube and centrifuged for 2 min at 12 000g. The supernatant was discarded, 330 L of leukocyte lysis reagent (280 mmol/L NaOH) added, and the cell pellet resuspended by vortexmixing. The sample was heated in a boiling water bath for 5 min, vortex-mixed to fully dissolve the cell debris, and then heated at 100°C for an additional 30 min. The solution was cooled and either used directly or stored at Ϫ70°C until required.
Assay setup and procedure. Determination of the factor V genotype by this assay is based ultimately on the comparison of the fluorescent signals obtained from each sample after hybridization and cross-linking of the sample DNA to different sets of allele-specific probes. Overviews of the assay format and procedure are shown in Figs. 1 and 2 .
Each processed sample was aliquoted (100 L) into three wells of a 96-well polypropylene microtiter plate (Corning Costar Corp.). One of three different probe solutions [50 L, containing 1.5 mol/L NaCl, 350 mL/L formamide, 5 g/L bovine serum albumin (BSA)] was added to each aliquot. The first probe solution contained six cross-linker-modified reporter probes (0.1 pmol each) complementary to a region of the factor V gene flanking the mutation site and a single cross-linker-modified capture probe (1 pmol) that was complementary to nucleotides 1683-1698 of the normal factor V gene: 5Ј-TXT TCC TCG CCT GTC C-3Ј (X denotes the position of the cross-linker in the probe). The second probe solution contained the same set of reporter probes as the first. However, the included capture probe was complementary to the mutant factor V (Leiden) gene sequence: 5Ј-TXT TCC TTG CCT GTC C-3Ј. A third, control, probe solution contained the reporter probe set and both the normal-and mutant-specific capture probes.
In addition to the samples, each assay plate also contained nine negative controls (unboiled leukocyte lysis reagent) and three positive controls. Each of the three Each individual patient sample is tested with three different probe solutions. The first solution contains six fluorescein-modified reporter probes that are complementary to sequences in exon 10 and intron 10 of the factor V gene and a single allele-specific biotinylated capture probe that is complementary to the normal factor V gene sequence. The second probe set contains the six reporter probes and a capture probe that is complementary to the factor V Leiden gene sequence. The third (control) probe solution contains the reporter probes and both capture probes. The fluorescent signals obtained after testing the sample with these probe solutions are used to determine the factor V status of the individual.
probe reagents was added to three negative control wells and one positive control well. Positive control wells contained an exon 10 -partial intron 10 PCR amplicon (50 amol) dissolved in leukocyte lysis reagent. The target DNA had been obtained previously by PCR amplification of DNA from a patient heterozygous for the factor V Leiden allele (see below for PCR procedure). After addition of the probe reagents to the samples and controls, 50 L of neutralization reagent (190 mmol/L citric acid, 300 mmol/L NaH 2 PO 4 , 1.5 mol/L NaCl, 4 mL/L Tween-20, 350 mL/L formamide) was added to each well. The loaded microplate was covered by a 2-mm-thick Pyrex TM filter and heated to 40°C by placing it on a microplate heater (USA/Scientific) that was positioned inside a UV cross-linking chamber 2.5 cm below the UV lamps (UV-A bulbs; UVP Model CL1000-L, UVP). The samples were incubated for 20 min and then irradiated for 30 min at the same temperature. The total energy delivered to the plate was ϳ30 mJ/cm 2 . After irradiation, the plate was removed from the heater and cooled to room temperature for 10 min. Next, 75 g of streptavidin-coated magnetic beads (Dynabeads ® M-280, Dynal) were added to each well to capture the cross-linked probe-target hybrids via the biotin residue attached to the allele-specific capture probes. After a 30-min incubation at room temperature the plate was placed on top of a set of bar magnets that were positioned between the wells under the plate such that the magnetic beads in each well formed a tight pellet towards one side of the U-shaped well bottom. After 30 s the liquid in each well was removed by aspiration and the plate taken off the magnet assembly. The beads were washed once by the addition of 225 L of wash reagent (1ϫ SSC, 1 mL/L Tween-20) to each well. The plate was again placed onto the magnet assembly and the wash reagent removed. The plate was then removed from the magnet. Immediately after washing the beads, 100 L of antifluorescein antibody-alkaline phosphatase conjugate (Boehringer Mannheim Corp.), diluted 1:3000 in 100 mmol/L Tris-HCl (pH 7.5), 150 mmol/L NaCl, 1 mL/L Tween-20, and 2.5 g/L BSA, was added to each well. The samples were incubated for 20 min at room temperature and then washed four times with 225 L of wash reagent by using the procedure described above. Upon completion of the final wash cycle, 100 L of an alkaline phosphatase substrate (Attophos TM , JBL Scientific) was added to each well and the plate incubated at 37°C for 60 min. Finally, the fluorescent product from the reaction of Attophos with alkaline phosphatase was detected by recording the fluorescence signal with a microplate fluorometer (Packard Instrument Co.).
data analysis
The net sample signal (NSS) was calculated by subtracting the mean signal of the three negative controls for each probe set (factor V normal, factor V Leiden, or both) from the signal obtained from a sample tested with the appropriate probe set. Negative values for the NSS were considered to be zero. Patient genotype determinations were based on the ratio of the NSS for the mutant (Leiden) probe set divided by the NSS for the normal probe set.
assay precision
Within-run and between-run precision were assessed by testing a sample obtained from peripheral blood from a single individual. For within-run precision, the sample was divided into six aliquots and the assay performed six times on the same plate. For between-run precision the sample was divided into six aliquots and one aliquot was tested each day for six consecutive days.
pcr amplification and genotype determination by mnlI digestion The assay involves seven basic steps: sample preparation (isolation and lysis of leukocytes), hybridization and cross-linking of allele-specific probes to factor V gene DNA, capture of the cross-linked probe-target complex onto streptavidincoated magnetic beads, washing to remove unhybridized probes, binding of an antibody-alkaline phosphatase conjugate to the probe-target complex, washing to remove unbound antibody, and development and detection of a fluorescent product that is obtained by the reaction between alkaline phosphatase and Attophos. Full details are provided in Materials and Methods.
with MnlI and genotype determined by fragment size after agarose gel electrophoresis as previously described [6] .
Results

overview of cross-linking hybridization assay for factor V leiden mutation
We have developed a technology based on the use of photocross-linkable probes for the direct detection of DNA/RNA targets in clinical samples [12] . The first tests developed involving this cross-linking system were for detection of infectious disease organisms such as Chlamydia trachomatis. We have recently expanded this assay platform to the detection of genetic defects, specifically single base mutations.
The format and procedure of the cross-linking assay for detection of the factor V Leiden mutation are outlined in Figs. 1 and 2 . Each sample was analyzed with three separate probe set combinations. The first test involved a probe set containing a capture probe complementary to the normal gene sequence, the second, a probe set containing a capture probe complementary to the mutant (Leiden) gene sequence, and the third, a probe set containing both normal and mutant capture probes. Assay conditions were optimized for minimal hybridization and cross-linking between probe/target combinations containing a mismatch, while permitting efficient hybridization and cross-linking between fully complementary probe/target combinations. The genomic DNA from an individual with two normal factor V alleles should yield a relatively strong signal when subjected to the normal capture probe set and a weak signal when subjected to the mutant probe set under the assay conditions. The reverse outcome should be true for individuals who are homozygous for factor V Leiden, i.e., those individuals whose factor V gene contains two mutant alleles. For individuals who are heterozygous for factor V Leiden (one copy of each allele), each probe set should yield approximately the same signal. The control test, which includes both capture probes, should always deliver the same relative signal, irrespective of genotype. The predicted relative signal intensities obtained from the three factor V genotypes after testing with the normal, mutant, and control probe sets should be 2, 0, and 2 for the normal genotype; 0, 2, and 2 for the factor V Leiden homozygote; and 1, 1, and 2 for the factor V Leiden heterozygote, respectively.
In reality, the absolute signal obtained from testing individuals with the same genotype will vary because of the amount of blood available for testing and variations in subject leukocyte concentration. Consequently, determination of the factor V genotype was based on the ratio of the NSS generated by the mutant (Leiden) probe set divided by the NSS generated by the normal probe set. Accordingly, the theoretical NSS ratios for a normal individual, a heterozygote, and a factor V Leiden homozygote should be 0, 1, and ϱ.
cross-linking hybridization assay performance
Assay performance with purified factor V gene fragments. Initial evaluations of assay performance were conducted with purified PCR amplicons derived from genomic DNA of a normal individual, a factor V Leiden heterozygote, and a factor V Leiden homozygote (see Table 1 ). These preliminary results indicated that the assay, as predicted, was capable of distinguishing all three genotypes, albeit with synthetic targets.
Assay performance with samples obtained from whole blood. To assess the potential clinical utility of the assay, whole blood was collected from a single individual previously determined to possess a normal factor V genotype (results not shown). To test signal response to cell concentration, the blood was divided into aliquots with three different leukocyte concentrations. Additionally, to evaluate the possible effect of storage and transport conditions, assays were carried out directly on leukocytes isolated from fresh or refrigerated blood and on previously isolated leukocytes stored at Ϫ70°C. The results in Fig. 3 show that sufficient signal for genomic resolution was obtained even at the lowest cell number tested (0.7 ϫ 10 7 leuko- Fig. 3 . Effect of sample storage and cell number on the performance of the factor V Leiden mutation assay.
Different concentrations of leukocytes (0.7 ϫ 10 7 -1.5 ϫ 10 7 ) obtained from an individual with a normal factor V genotype were tested in the cross-linking hybridization assay with probe solutions designed to detect the normal factor V allele (normal probes), the factor V Leiden allele (Leiden probes), and both alleles (both probes). Assays were carried out on leukocytes that had been isolated from fresh blood, leukocytes that had been isolated from blood that had been stored for 3 days at 4°C, and leukocytes that had been isolated from fresh blood and stored at Ϫ70°C for 3 days.
cytes/test well). Furthermore, the performance of the assay was not altered significantly as a result of the three sample processing methods tested. The data showed that, as expected, the assay signal increased with increased concentrations of leukocytes tested. However, unlike experiments with purified DNA targets in which we observed a direct correlation between target concentration and the level of signal generated (data not shown), doubling the leukocyte concentration produced only a marginal increase in assay signal. We believe that this effect can be attributed to a reduction in the efficiency of the leukocyte lysis step (during sample preparation) when larger numbers of leukocytes are processed. Greater concentrations of leukocytes lead to an overall increase in the volume of the lysis solution and a concomitant reduction in the NaOH concentration in the solution. In addition, some neutralization of the NaOH may occur through buffering caused by the release of cell contents during cell lysis. Combined, these effects may contribute to lower than expected signal generation; increasing the volume of the lysis solution leads to a simple reduction in target concentration, whereas reducing the NaOH concentration leads to less efficient cleavage of the genomic DNA into the range of smaller-sized DNA fragments that are required for optimal hybridization (data not shown).
Precision studies were carried out to determine the within-run and between-run reproducibility of the assay. Within-run precision was calculated after performing the assay on six identical samples (normal factor V genotype), whereas between-run precision was determined after testing of a single same sample each day for 6 days. The results of these experiments, shown in Table 2 , indicated that within-run and between-run CVs were within acceptable limits. Although the data indicated slightly better between-run precision than within-run precision, we note that the sample size (n ϭ 6) for these studies was relatively small. It is reasonable to conclude that the within-run CVs determined here (8.3-10 .1%) are a realistic representation of the precision of this assay.
Testing of patient samples. The factor V Leiden status of 122 patients referred for evaluation for deep vein thrombosis were tested by the cross-linking hybridization assay and by the standard PCR amplification-MnlI restriction enzyme analysis; the latter method is currently considered the gold standard for factor V Leiden mutation testing. Fourteen of these individuals were determined by the PCR amplification method to be heterozygous for the factor V allele; the remaining 108 were normal.
Between 0.5 and 4 mL of whole blood from each individual was tested by the cross-linking hybridization assay to determine their factor V genotype. Since the leukocyte concentration in the blood samples was not determined before testing, the amount of genomic DNA assayed in each sample was unknown. However, assuming a normal range of leukocyte concentration in whole blood of ϳ4 ϫ 10 9 -11 ϫ 10 9 cells/L, we estimate that the amount of factor V gene target copies present in each test well was between 2 and 40 amol.
After testing of the patient samples by the cross-linking hybridization assay, the ratio of the NSS for the mutant (Leiden) probe set divided by the NSS for the normal probe set was calculated for each sample. The ratios obtained for all 122 samples are summarized in Fig. 4 . The mutant/normal NSS ratios for the 108 normal individuals fell between 0 and 0.26 (mean ϭ 0.06; mean ϩ 4 SD ϭ 0.31), whereas the 14 heterozygous individuals fell between 0.47 and 1.32 (mean ϭ 0.76); clear separation was observed between the two groups of patients with no overlap. On the basis of these limited results, a mutant/ normal NSS ratio of 0.35 could be used as a lower limit for indicating factor V Leiden heterozygosity. None of the patients referred during the time period of this study was homozygous for the factor V Leiden allele; however, the PCR amplicon data shown above suggested that the cross-linking hybridization method would also clearly distinguish homozygotes from heterozygotes.
The data obtained from the control probe set containing both factor V allele-specific capture probes was not used to calculate factor V genotype. However, in a commercial version of this assay the data from the control would be used to ensure that the NSS values obtained from the two individual probe sets fell within acceptable limits for any given genotype. At the completion of the 122-patient study the ratios were obtained by dividing the NSS for the normal probe set by the NSS for the control probe set and by dividing the NSS for the mutant (Leiden) probe set by the NSS for the control probe set. For the 108 
Discussion
A nucleic acid-based diagnostic platform that integrates cross-linking offers significant advantages over conventional hybridization-based assays. By covalently joining the hybridized probe and target nucleic acids, the amount of target retained throughout the assay procedure is maximized, thereby ensuring the highest possible signal. Furthermore, because of the fact that covalently linked hybrids are far more stable than conventional duplex strands, adventitiously bound signal-generating probes may be more efficiently removed from the test sample with washing procedures of higher stringency, thus effectively lowering background. In this study, an oligonucleotide cross-linking technology has been used to directly detect the factor V Leiden genotype without the prior DNA purification, amplification, or restriction enzyme analysis steps of the current PCR assay. The results from testing 122 patient samples were in total agreement with the gold standard PCR-based method; discrimination between normal and heterozygous individuals was unambiguous. The direct assay offers certain advantages over the PCR method. For example, the assay does not have problems inherent to PCR such as sample inhibition and false results due to reaction contamination. In addition, PCR methods rely on equal amplification of both genomic strands. Preferential amplification of one strand may mask the presence of the other and lead to incorrect diagnosis of heterozygous individuals.
The 96-well microtiter plate format allows for simultaneous processing of multiple patient samples. Since 12 wells are occupied by controls, a maximum of twelve samples (36 wells) may be processed during one session (the assay has a maximum capacity of 48 usable wells due to the design of the magnet assembly). The entire assay procedure, including sample preparation, can be completed in under 5 h. An instrument that automates all steps of the assay procedure, including reagent addition, cross-linking, washing, and fluorescence detection, is currently under development. The instrument utilizes all 96 wells, thereby increasing the single-run testing capacity to 28 samples. With automation, the only manual steps remaining are those associated with sample preparation.
In conclusion, we have developed a direct assay to test for the factor V Leiden mutation that is based on nucleic acid cross-linking technology. The assay is sensitive and cleanly discriminates the normal and mutant alleles. We are currently enhancing the sensitivity of this assay by expanding the reporter probe set to cover more sequence of the gene surrounding the mutation site. This crosslinking technology is also being applied in the development of assays for other genetic diseases.
